Disease areas:
  • bones, joints and muscles
Last updated:
Author(s):
Rikke Linnemann Nielsen, Thomas Monfeuga, Robert R. Kitchen, Line Egerod, Luis G. Leal, August Thomas Hjortshøj Schreyer, Frederik Steensgaard Gade, Carol Sun, Marianne Helenius, Lotte Simonsen, Marianne Willert, Abd A. Tahrani, Zahra McVey, Ramneek Gupta
Publish date:
1 April 2024
Journal:
Nature Communications
PubMed ID:
38561399

Abstract

Osteoarthritis (OA) is increasing in prevalence and has a severe impact on patients’ lives. However, our understanding of biomarkers driving OA risk remains limited. We developed a model predicting the five-year risk of OA diagnosis, integrating retrospective clinical, lifestyle and biomarker data from the UK Biobank (19,120 patients with OA, ROC-AUC: 0.72, 95%CI (0.71-0.73)). Higher age, BMI and prescription of non-steroidal anti-inflammatory drugs contributed most to increased OA risk prediction ahead of diagnosis. We identified 14 subgroups of OA risk profiles. These subgroups were validated in an independent set of patients evaluating the 11-year OA risk, with 88% of patients being uniquely assigned to one of the 14 subgroups. Individual OA risk profiles were characterised by personalised biomarkers. Omics integration demonstrated the predictive importance of key OA genes and pathways (e.g., GDF5 and TGF-β signalling) and OA-specific biomarkers (e.g., CRTAC1 and COL9A1). In summary, this work identifies opportunities for personalised OA prevention and insights into its underlying pathogenesis.

Related projects

The aim of the proposed research is to understand comorbidities in cardiometabolic diseases. In particular, to answer the following questions: what are the biological mechanisms…

Institution:
Novo Nordisk Research Centre Oxford Ltd, Great Britain

The primary scientific goal of this research project is to apply multiplex proteomic profiling of 56,000 UK Biobank plasma samples to facilitate the identification of…

Institution:
Pfizer Inc, USA, United States of America

All projects